DPFS Devolved Portfolio (Pilot)
Lead Research Organisation:
University of Edinburgh
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).
Organisations
- University of Edinburgh (Lead Research Organisation)
- Mauna Kea Technologies (Collaboration)
- Astex Pharmaceuticals (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Cambridge Cognition Ltd (Collaboration)
- University of Dundee (Collaboration)
- TheraKIND (Collaboration)
- Eagle Designs (Collaboration)
- Queen Elizabeth Hospital Birmingham (Collaboration)
- University of Pennsylvania (Collaboration)
- Johns Hopkins University (Collaboration)
- Selcia (Collaboration)
- Debiopharm (Collaboration)
- NATIONAL CENTRE FOR SOCIAL RESEARCH (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Royal Infirmary of Edinburgh (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- University of Iowa (Collaboration)
- University Medical Center Gronigen (Collaboration)
People |
ORCID iD |
Publications
Hiscox LV
(2016)
Magnetic resonance elastography (MRE) of the human brain: technique, findings and clinical applications.
in Physics in medicine and biology
Tieges Z
(2013)
Abnormal level of arousal as a predictor of delirium and inattention: an exploratory study.
in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Hall RJ
(2013)
Delirium and cerebrospinal fluid S100B in hip fracture patients: a preliminary study.
in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Mitchell R
(2015)
TRP Channels as Therapeutic Targets
| Description | Cerebral Aging (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Imaging for Human Health Royal Society of Chemistry (Functional Optical Imaging in mice and man) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | MSc in Surgical Science (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Medical SAB (Functional Optical Imaging in mice and man) |
| Geographic Reach | Asia |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Advice to Mauna Kea technologise on implementation of probes into medical practice. |
| Description | President of the European Delirium Association (New neuropsychological instrument for the diagnosis and monitoring of delirium |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | RSC (Functional Optical Imaging in mice and man) |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Scottish Delirium Association (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Surgical Science MSc (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | 5?-reduced glucocorticoids and angiogenesis (Abernethie A with Andrew R, Hadoke PWF, Walker BR) |
| Amount | £140,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2020 |
| Description | 5a-Tetrahydrocorticosterone (5aTHB); DPFS |
| Amount | £850 (GBP) |
| Organisation | Edocrine Societies |
| Sector | Public |
| Country | United States |
| Start | |
| Description | 5a-Tetrahydrocorticosterone (5aTHB); a pathway to a novel, safer, topical anti-inflammatory glucocorticoid (Andrew R, Walker BR, Webster SP |
| Amount | £73,218 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Institutional Strategic Support Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Analytical Science Digital Signal Processing |
| Amount | £11,600,000 (GBP) |
| Funding ID | EP/K03197X/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 08/2018 |
| Description | BHF Studentship (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) |
| Amount | £120,000 (GBP) |
| Organisation | University of Glasgow |
| Department | British Heart Foundation Unit |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 09/2015 |
| Description | Clinical Research Fellowship EDTB2 delirium and stroke patients |
| Amount | £230,000 (GBP) |
| Funding ID | RTF17/0111 |
| Organisation | The Dunhill Medical Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 09/2015 |
| Description | DPAK GSK (KMO inhibitors) |
| Amount | £1,300,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 10/2012 |
| End | 10/2015 |
| Description | DPFS Dell App -Biomedical Catalyst |
| Amount | £1,170,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 12/2019 |
| Description | ERI IKTF TRPM8 hit discovery |
| Amount | £12,500 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 02/2013 |
| Description | Early Career Grant (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs) |
| Amount | £10,000 (GBP) |
| Organisation | Society for Endocrinology |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Edinburgh BioQuarter Del Box |
| Amount | £4,000 (GBP) |
| Funding ID | GQ2353 |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2012 |
| End | 08/2012 |
| Description | Edinburgh Delirium Test Centenary Award to Dr Zoe Tieges. |
| Amount | £25,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 12/2018 |
| Description | Edinburgh Delirium Test Development and validation of the 4AT: a new rapid screening tool for delirium. |
| Amount | £820,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Department | MRC National Institute for Medical Research (NIMR) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 01/2020 |
| Description | Health Innovation Challenge Fund (Functional Optical Imaging in mice and man) |
| Amount | £2,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2011 |
| End | 08/2014 |
| Description | IKTF (TRPM8 agonist compound expansion) |
| Amount | £12,500 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 10/2013 |
| Description | IKTF (functional readout TRPM8 agonists) |
| Amount | £15,000 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 10/2013 |
| Description | Initiating Knowledge Transfer Fund (TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Amount | £7,600 (GBP) |
| Organisation | Government of Scotland |
| Department | Scottish Funding Council |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Lifelong Health and Wellbeing Edinburgh Delerium Box |
| Amount | £3,400,000 (GBP) |
| Funding ID | G0700704/84698 |
| Organisation | Medical Research Council (MRC) |
| Department | Lifelong Health and Wellbeing (LLHW) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 01/2018 |
| Description | MRC Centenary Fund EDTB2 software based applications |
| Amount | £25,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 09/2013 |
| Description | MRC DCS (Functional Optical Imaging in mice and man) |
| Amount | £2,357,633 (GBP) |
| Funding ID | MR/J010901/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2013 |
| End | 12/2015 |
| Description | MRC DPFS (Functional Optical Imaging in mice and man) |
| Amount | £960,056 (GBP) |
| Funding ID | MR/J014702/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 08/2015 |
| Description | MRC/AZ(Functional Optical Imaging in mice and man) |
| Amount | £250,000 (GBP) |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 12/2012 |
| End | 12/2013 |
| Description | Maurice Wohl (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Amount | £50,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2012 |
| End | 03/2015 |
| Description | NC3R MRC DPFS (Functional Optical Imaging in mice and man) |
| Amount | £100,000 (GBP) |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Peri-operative Enhanced Recovery hip Fracture Care of patients with Dementia |
| Amount | £1,960,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Department | MRC National Institute for Medical Research (NIMR) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 02/2020 |
| Description | PhD Studentship (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) |
| Amount | £130,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | RSCEd Small Project Grant (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Amount | £7,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2012 |
| End | 03/2013 |
| Description | SULSA-supported Scottish Hit Discovery Facility (SHDF) (TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Amount | £30,500 (GBP) |
| Organisation | Scottish Universities Life Sciences Alliance |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Society of Endocrinology Early career Grant (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) |
| Amount | £10,000 (GBP) |
| Organisation | Society for Endocrinology |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2013 |
| End | 04/2015 |
| Description | TENOVUS Small Research Grant (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Amount | £10,000 (GBP) |
| Organisation | Tenovus Cancer Care |
| Department | Tenovus Scotland |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2012 |
| End | 03/2013 |
| Description | mini project British Heart Foundation |
| Amount | £1,500 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2016 |
| End | 05/2019 |
| Title | Cell lines and assays (TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Description | • Cell lines o TRPM8 o TRPV1 o TRPA1 • Assays o TRPM8 o TRPV1 o TRPA1 • In vivo animal models • Compound Library • Database of compounds and results • High throughput screen All these assets have been logged as Invention Disclosures within the University of Edinburgh Tech Transfer Office (Edinburgh Research and Innovation) |
| Type Of Material | Biological samples |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | SULSA screen at Dundee Hit Discovery Unit. Positive outcome. |
| Title | Cyclophilin isoform proteins (Cyclophilin inhibitors as anti-viral therapies) |
| Description | developed protocols to produce all medically important isoforms of the the cyclophilin family (CypA,B,C,D,) in milligram quantities |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | expand potential discovery programmes for new cyclophilin indications. |
| Title | EDTB2 (New neuropsychological instrument for the diagnosis and monitoring of delirium |
| Description | The MRC DPFS grant funded the design and manufacture of the 'Edinburgh Delirium Test Box' version 2. Six devices were manufactured. Essentially the EDTB2 is seen as having the potential to make attentional deficits in delirium more measurable both in terms of detection of deficits, and severity grading. Measurement in delirium is acknowledged to be a priority area; there is no consensus on what outcome measures should be used in trials. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | We presented preliminary data from the EDTB2 at the European Delirium Association conference in Umea, Sweden, in Nov 2011. The EDTB1 and EDTB2 have attracted substantial attention, with two firm collaborations set up involving the EDTB2, and multiple other enquiries. |
| Title | EDTB2 (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Description | Manufacture of 4 further devices for use in MSc and PhD projects and US collaborations. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Continuing interest in measurement of delirium using the EDTB2 device and impact on clinical management |
| Title | EDULISS (Cyclophilin inhibitors as anti-viral therapies) |
| Description | The data-mining resource EDULISS (developed by Kun Yi Hsin and Steven Shave) is now freely accessible as a web-based resource (http://eduliss.bch.ed.ac.uk/test/ Nucleic Acids Res. 2011 : D1042-D1048) |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | Two researchers associated with the programme further optimised EDULISS as part of ongoing research. A freely available tool should enhance SBDD projects. |
| URL | http://eduliss.bch.ed.ac.uk/test/ |
| Title | Fragment screening (Cyclophilin inhibitors as anti-viral therapies) |
| Description | protocols to enable fragment-based screening on crystals of the drug targets CypA, B and D and generated over 30 new structures for deposition in the PDB |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | this has provided unique insight into novel compounds leading towards achievement of LTP |
| Title | ICB-Morph (Cyclophilin inhibitors as anti-viral therapies) |
| Description | ICB-Morph; a software package for designing non-peptide analogues based on natural peptide ligands |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | NA |
| Title | Scaffold data base (Cyclophilin inhibitors as anti-viral therapies) |
| Description | ICB-SSCore; a database containing over 200 small molecular scaffold combinatorial chemistry libraries designed for bead-based synthesis giving approximately 10 trillion synthetic possibilities |
| Type Of Material | Biological samples |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | novel insights in other targets |
| Title | Sreening reagents (KMO Inhibitors) |
| Description | Multiple cell lines for use in drug screens have been generated. Off-target screening assays have been developed. High throughput screening assays have been developed. Refinements of disease models have been made for the assessment of efficacy in rodents. a new in vivo pharmacodynamic/pharmacokinetic model has been generated |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | Manfred Auer Team Edinburgh GSK DPAc |
| Title | compound library (TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Description | Library of over 50 compounds with extensive SAR including in vivo model assessment for best performing compounds |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | supported validation of target and acceptance of tractability |
| Title | compounds (Cyclophilin inhibitors as anti-viral therapies) |
| Description | 10,500 compounds have been prepared that can probe the key site for inhibition of cyclophilin that will contribute to SBDD projects across cyclophilin targets. |
| Type Of Material | Biological samples |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Approaching potency and selectivity target. |
| Title | new compounds to sense enzyme activity (Functional Optical Imaging in mice and man) |
| Description | 24 new compounds with diverse functions to sense enzyme activity in vivo for experimental models and man |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Selected compound will be tested in man as potential in vivo diagnosis for lung inflammation and potential treatments |
| Title | single molecule assay (Cyclophilin inhibitors as anti-viral therapies) |
| Description | A single molecule spectroscopic assay has been developed based on a fluorescently labelled high affinity cyclophilin binder providing a unique tool for miniaturised binding and competition studies. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Key technique for developing library screening approaches |
| Title | skin irritation and allergy and skin ultrasound (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) |
| Description | in vivo methods developed and adapted for project |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Provided To Others? | No |
| Impact | demonstrated significant efficacy for test material equivalent to standard of care with reduced side effects. |
| Description | A new paradigm for testing pathway tractibility in lung disease |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Mechanisms for disease call - Astra Zeneca |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | University is developing new imaging agents |
| Collaborator Contribution | AstarZeneca are providing valuable input |
| Impact | too early |
| Start Year | 2013 |
| Description | A novel topical anti-inflammatory agent -development with Therakind |
| Organisation | TheraKIND |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | working up complex collaborative funding applications |
| Collaborator Contribution | working up complex collaborative funding applications |
| Impact | applications submitted |
| Start Year | 2013 |
| Description | Alternative screening (KMO Inhibitors) |
| Organisation | University of Edinburgh |
| Department | School of Biological Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The DPFS research team have contributed the screening cascade |
| Collaborator Contribution | Manfred Auer laboratory provides the application of miniaturised, ultra-high throughput screening platforms for the identification and validation of lead compounds for drug discovery and tool compounds for basic research. His "Integrated Chemical Biophysics" platforms (ICB) include in-silico design and screening, tagged one-bead one compound library production and screening on the surface of beads and chips, in solution, in cells and in model organisms. ICB platforms combine chemical, biological, and physical approaches to overcome many of the limitations of the current industrial early drug-discovery process |
| Impact | Too early for comment |
| Start Year | 2010 |
| Description | Astex (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Organisation | Astex Pharmaceuticals |
| Department | Astex Therapeutics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The DPFS team have evaluated the performance of the compound in detailled biochemical cellular and in vivo experiments |
| Collaborator Contribution | Astex have provided clinical compound AT13387 for the project and all information contained in the Investigators Broachure |
| Impact | We are now discussing how to develop an orphan drug application and clinical protocol. |
| Start Year | 2009 |
| Description | DPFS Dell App |
| Organisation | Cambridge Cognition Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Edinburgh bring extensive basic and clinical experience in delirium testing both pen and paper, the Del Box and recently the Del App. The collaboration is supported by a DPFS grant. |
| Collaborator Contribution | Cambridge Cognition develop and sell products for testing cognition primarily for AD. |
| Impact | Join application for Biomedical Catalyst funding |
| Start Year | 2016 |
| Description | DPFS Topical anti-inflamatory |
| Organisation | Queen Elizabeth Hospital Birmingham |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | providing compound and science 5?THB |
| Collaborator Contribution | investigating mechanisms of 5?THB action in DUSP1 KO mice. |
| Impact | too early |
| Start Year | 2013 |
| Description | Debiopharm (Cyclophilin inhibitors as anti-viral therapies) |
| Organisation | Debiopharm |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | Debiopharm are active in the area of cylophilin inhibitors we are looking for novel chemistry and approaches. |
| Collaborator Contribution | compound testing and intellectual contribution |
| Impact | Debiopharm may be the exit for the project as the compounds generated are getting closer to LTP |
| Start Year | 2009 |
| Description | Dundee SULSA Screen (TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Organisation | University of Dundee |
| Department | Division of Biological Chemistry and Drug Discovery |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The team provided the TRPM8 cell based screen and work extensively with the partner in transfer and validation. Scottish Universities Life Sciences Alliance (SULSA) is a research pooling partnership between the Universities of Aberdeen, Dundee, Edinburgh, Glasgow, St Andrews and Strathclyde that is supported by the Scottish Funding Council. |
| Collaborator Contribution | A library of 16,000 compounds was screened against the target identifying hits and new chemical scaffolds suitable for a medicinal chemistry programme |
| Impact | The 'hits' from the screen have been validated in the Mitchell laboratory and 5 compounds have been identified as potential new lead compounds. Cell biologists -DPFS Edinburgh Screening technologists Dundee |
| Start Year | 2010 |
| Description | EDTB2 ICU ERI (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Organisation | Royal Infirmary of Edinburgh |
| Department | Intensive Care Unit (ICU) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Provision of EDTB2 and expertise to enable a MHRA approved programme |
| Collaborator Contribution | ICU consultants evaluated the device |
| Impact | Clinical trial results |
| Start Year | 2012 |
| Description | EDTB2 Iowa (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Organisation | University of Iowa |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | We are providing EDTB2 as part of collaboration where we instigated interest in using our device for measuring delirium |
| Collaborator Contribution | Setting up clinical collaborations, where EDTB2 will be provided at cost. This has propelled project to investigate and obtain appropriate approvals. |
| Impact | NA |
| Start Year | 2011 |
| Description | EDTB2 Johns Hopkins (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Organisation | Johns Hopkins University |
| Department | School of Medicine Johns Hopkins |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provision of EDT2 |
| Collaborator Contribution | Setting up clinical collaborations, where EDTB2 will be provided at cost. This has propelled project to investigate and obtain appropriate approvals. assisted with developing specification for product suitable for US use |
| Impact | none |
| Start Year | 2011 |
| Description | EDTB2 Pennsylvania (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Organisation | University of Pennsylvania |
| Department | Perelman School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Introduced potential of EDTB2 for determination of Delirium |
| Collaborator Contribution | Setting up clinical collaborations, where EDTB2 will be provided at cost. This has propelled project to investigate and obtain appropriate approvals. assisted with developing specification for product suitable for US use |
| Impact | NA |
| Start Year | 2011 |
| Description | EDTB2 Tablet PC (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Department | Medical Devices Unit |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Provision of EDTB2 device, supporting data and computer software. |
| Collaborator Contribution | Developing a tablet PC-based software version of the EDTB2 tasks. |
| Impact | First version complete. Pilot studies programmed for 2013 |
| Start Year | 2012 |
| Description | Eagle Designs (New neuropsychological instrument for the diagnosis and monitoring of delirium) |
| Organisation | Eagle Designs |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Clinical evaluation and practical utility of device designs |
| Collaborator Contribution | Built on existing collaboration on version 1 of device to develop version 2 and contribution to patent application. |
| Impact | The MRC DPFS grant funded the design and manufacture of the 'Edinburgh Delirium Test Box' version 2. Six devices were manufactured. For background: the 'Edinburgh Delirium Test Box' version 1 was designed and manufactured funded as part of an MRC Clinician Scientist Fellowship to AMJ MacLullich; this work resulted in a publication (Brown et al. J Neurol Neurosurg Psych 2011 Dec;82(12):1334-40; Epub in Jun 2010). This publication was the 'Patient's Choice' for that issue of the journal |
| Start Year | 2008 |
| Description | GSK DPAc (KMO Inhibitors) |
| Organisation | GlaxoSmithKline (GSK) |
| Department | Discovery Partnerships with Academia |
| Country | Global |
| Sector | Private |
| PI Contribution | MRC DPFS support for our drug discovery activities has directly enabled the initiation a major industrial partnership with GSK as part of its Discovery Partnerships with Academia (DPAc) scheme. The collaboration is one of only ten to be awarded worldwide. MRC DPFS funding directly enabled the translation of fundamental biology into the role of a key metabolic enzyme in multiple organ failure and the subsequent discovery on novel enzyme inhibitors. This intellectual property forms the basis of the collaboration with GSK to develop new drugs for the treatment of multiple organ failure.http://www.edinburghbioquarter.com/news/2011/10/the-university-of-edinburgh-and-glaxosmithkline-gsk-agree-collaborative-partnership-for-drug-discovery.htm). The project has now completed its first milestone and is on course to fulfil the next milestone ahead of schedule. Update at Jan 2016, project has now passed clinical candidate selection point. The drug candidate is now in pre-clinical testing and is due to enter human clinical trials end 2018/early 2019. |
| Collaborator Contribution | GSK will provide industrial strenght medicinal chemistry and screening and onwards into pre-clinical and clinical developemnt |
| Impact | Further support for the CMVM Drug Discovery Unit http://www.edinburghbioquarter.com/news/2011/10/the-university-of-edinburgh-and-glaxosmithkline-gsk-agree-collaborative-partnership-for-drug-discovery.htm). |
| Start Year | 2011 |
| Description | Mauna Kea Technologies Optical Equipment (Functional Optical Imaging in mice and man) |
| Organisation | Mauna Kea Technologies |
| Country | France |
| Sector | Private |
| PI Contribution | Our research devloped the unique probes that will greatly enhance the clinical utility of Mauna Kea Technologies equipment. Other companies also provide/are developing similar technology so that we will have options for multiple routes to market |
| Collaborator Contribution | Mauna Kea Technologies provide the optical equipment used to detect the probes in the lung. |
| Impact | Probes tested in vivo in sheep lung using Mauna Kea Technologies equipment. Positive data obtained. formal partnership to develop a bespoke device for use with probes |
| Start Year | 2010 |
| Description | Mechanism of AT13387 AB (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Organisation | University of Edinburgh |
| Department | Centre for immunity, infection and evolution |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | EH brings expertise in renal transplatation |
| Collaborator Contribution | Dr Amy Buck brings expertise in miRNA to the investigation of roll of AT13387 in organ protection |
| Impact | research results on mechanism of action |
| Start Year | 2012 |
| Description | Mechanism of AT13387 JH (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Organisation | University of Edinburgh |
| Department | MRC Centre for Inflammation Research |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | EH brings experience of renal transplant models and practice |
| Collaborator Contribution | Prof Jeremy Hughes Dr David Kluth provide expertise in immunology |
| Impact | data on mechanism of action of AT13387 in macrophages in AT13387 mediated renal protection |
| Start Year | 2012 |
| Description | Medical Physics (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) |
| Organisation | Royal Infirmary of Edinburgh |
| Department | Intensive Care Unit (ICU) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | novel approach to topical antiinflamatory medicine |
| Collaborator Contribution | novel approach to analysis of inflammation using Ultra-sound |
| Impact | in progress |
| Start Year | 2012 |
| Description | PhD alternative screening (KMO inhibitors) |
| Organisation | University of Edinburgh |
| Department | School of Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | KMO inhibitor project bring a validated target and a screening cascade for the serious un-met need of acute pancreatitis |
| Collaborator Contribution | The Auer laboratory are establishing novel platforms for bead based screening of directed libraries. |
| Impact | New screening technologies have been developed and early identification of new inhibitors is in place. |
| Start Year | 2011 |
| Description | Pig Model Development EC (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Organisation | University of Edinburgh |
| Department | Royal School of Veterinary Studies |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | EH brings expertise in renal transplant to the vet school |
| Collaborator Contribution | Professor Eddie Clutton provides porcine model |
| Impact | research results |
| Start Year | 2012 |
| Description | Pig Model Development RP (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) |
| Organisation | University Medical Center Gronigen |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | Expertise in the mouse renal transplant model |
| Collaborator Contribution | EH is seconded to the post in the Netherlands at the moment, developing the pig model, which is directly related to this project and non-MRC funded. |
| Impact | developemnt of the pig model of efficacy |
| Start Year | 2011 |
| Description | SULSA (Cyclophilin inhibitors as anti-viral therapies) |
| Organisation | National Centre for Social Research |
| Department | Scottish Centre for Social Research (ScotCen) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Providing a cutting edge drug discovery project with novel stucture based drug design and screening approaches that were aligned to the setting up of the SULSA infrastructure |
| Collaborator Contribution | Using 6 SULSA researchers over short projects 3-12 months key aspects of the project were advanced where they were aligned with the general skill infrastructure development of the SULSA team. this included library synthesis, medicinal chemistry, biophysical screening, virtual library design and spectroscopic assay design. |
| Impact | This collaboration has allowed the project to attempt multiple approaches towards building peptidomimetics that would have been unavailable to the project under DPFS funding alone. The DPFS funding has been catalytic in harnesing other contributions. Additionally this included 2 contribution from 2 masters students. |
| Start Year | 2009 |
| Description | Selcia (Cyclophilin inhibitors as anti-viral therapies) |
| Organisation | Selcia |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Structure based drug design |
| Collaborator Contribution | Intellectual contribution to chemistry approaches |
| Impact | Continuous provision of ultra high quality proteins |
| Start Year | 2010 |
| Description | Ultra-sound measurements (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) |
| Organisation | University of Edinburgh |
| Department | Medical Physics & Medical Engineering Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with Dr Carmel Moran, Medical Physics and Manager Ultra-sound facility. |
| Collaborator Contribution | developing efficacy measure |
| Impact | methods of efficacy detection using ultrasound as a method to measure skin thinning |
| Start Year | 2011 |
| Title | APPARATUS AND METHOD FOR TESTING SUSTAINED ATTENTION AND DELERIUM |
| Description | A testing apparatus for testing a user's sustained attention comprises at least one stimulus-provider and a controller for controlling the stimulus-provider to provide at least one target stimulus, wherein the controller is configured to perform at least one operating procedure and the or each operating procedure comprises controlling the stimulus-provider to provide a sequence of target stimuli to the user. |
| IP Reference | US2012271194 |
| Protection | Patent application published |
| Year Protection Granted | 2012 |
| Licensed | Commercial In Confidence |
| Impact | Commercial potential underpinned and consolidation with other attention devices under evaluation as a new spin out. |
| Title | INDUCTION OF ANALGESIA IN NEUROPATHIC PAIN |
| Description | The present invention relates to agents which are capable of inducing analgesia in chronic neuropathic pain, associated methods and uses thereof. In particular, the present invention provides compounds capable of activating the TRPM8 receptor for the treatment of chronic neuropathic pain. |
| IP Reference | WO2008015403 |
| Protection | Patent application published |
| Year Protection Granted | 2008 |
| Licensed | No |
| Impact | The protection has supported the evaluation of a menthol gel for treatment of cancer induced neuropathic pain. The positive trial supports the selection of the TRPM8 programme as a fast follower to the menthol product |
| Title | METABOLITE |
| Description | The present invention relates to the modulation of glucocorticoid metabolism. In particular the invention relates to the modulation of the functional activity of the glucocorticoid receptor by 5alpha reduced metabolic breakdown products of glucocorticoids. |
| IP Reference | WO03105838 |
| Protection | Patent granted |
| Year Protection Granted | 2003 |
| Licensed | No |
| Impact | The project has been able to demonstrate efficacy of the metabolite proposed in the patent. This will support a significant business proposition of granted patent and naturally circulating compound. |
| Title | Metabolite |
| Description | The present invention relates to the modulation of glucocorticoid metabolism. In particular the invention relates to the modulation of the functional activity of the glucocorticoid receptor by 5alpha reduced metabolic breakdown products of glucocorticoids. |
| IP Reference | US2005130946 |
| Protection | Patent granted |
| Year Protection Granted | 2005 |
| Licensed | No |
| Impact | Has provided valuable commercial protection for this translational programme |
| Title | Optical imaging probes (Functional Optical Imaging in mice and man) |
| Description | Probes that will change wavelenght when subjecyed to enzymes in activated neutophiles. |
| IP Reference | GB1106004.3 |
| Protection | Patent application published |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | A total of £10.51 million has been obtained in follow on funding and a company formed to develop the broad technology. A non exclusive collaboratoration deal is in place with Mauna Kea on development of bespoke equipment. The spin-out has an investment of £4M to commercialise the technology |
| Title | 5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs) |
| Description | "Glucocorticoids are amongst the most widely prescribed drugs but their use is limited by metabolic and bone adverse effects. We have identified endogenous anti-inflammatory glucocorticoids which lack some adverse effects. The lead compound is 5a- tetrahydrocorticosterone (5aTHB). We now aim to evaluate its efficacy in further models of inflammation and to detail its side-effect profile. More comprehensive proof-of-principle data will unlock follow-on funding to support "first in man" studies and optimise the lead drug, initially for topical use in skin disease. Specifically, 5aTHB will be studied: 1) Anti-inflammatory efficacy will be compared with hydrocortisone in murine models of skin inflammation and arthritis. 2) Pharmacokinetic parameters will be assessed in mice. 3) Metabolic, skin and bone toxicities will be compared to hydrocortisone at equivalent antiinflammatory doses in mice. Results will determine the potential of 5aTHB as topical and/or systemic therapy as a safer alternative to current first line therapy with conventional glucocorticoids. Most recent work supported by DPFS Portfolio Award" |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | tbc |
| Title | A pharmacological pre-conditioning agent to reduce organ injury in transplantation |
| Description | Despite great improvements in outcome following organ transplantation, the incidence of graft failure remains high. Our research focuses on developing pharmacological strategies to reduce ischemia/reperfusion injury (IRI), the main contributor to early graft failure. Our aim is improve the function and longevity of transplanted organs by administering a single dose of an agent to a multi-organ donor prior to organ retrieval. This would prime protective cellular mechanisms in anticipation of the injurious nature of ischemia, cold storage and reperfusion. We are investigating a number of candidate compounds at the molecular level and are studying the most promising in a mouse model of renal IRI. For instance, using heat shock protein 90-binding agents (HBA), we have demonstrated upregulation of protective heat shock proteins in the heart, lungs, liver and kidneys and shown a functional and morpholgical renal protection. We are now in a position to extend our research portfolio and examine these agents in a phase 1 trial. Intellectual Property protection: Patent GB0710781.6 (University of Edinburgh, June 2007, PCT: WO2008/149103) covers the use of KMO inhibitors in organ failure and methods of monitoring therapy. Most recent work supported by DPFS Portfolio Award and a collaboration with Astex Therapeutics. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | tbc |
| Title | Cyclophilin inhibitors as anti-viral therapies. |
| Description | Cyclophilin (CypA) is a target for HIV and HCV infection. The only pharmacologically useful molecules known to inhibit CypA are cyclopsporines (CsA). Non-immunosuppressive CsA analogues are showing promising in phase 2 clinical trials for HCV infection. Based on virtual screening and structural studies we have identified six different chemical scaffolds that inhibit cylophilin isomerise activity in the low micromolar range. Modelling studies show that with appropriate chemical derivitisation the scaffolds could be turned into lead compounds for drug development. We will design, synthesise and screen large bead-based libraries of compounds (thousands to hundreds of thousands, depending on SAR and building block availability). This approach will enable us to identify submicromolar binders and generate SAR binding data from primary screening. Viral screens will be carried out with our potential commercial partners (Debiopharm, Switzerland). Leads generated would represent first in class lmw non-peptide CypA inhibitors. Most recent work supported by DPFS Portfolio Award and included a collaboration with Debiopharm. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | Multiple new tools and approaches to SBDD established. |
| Title | DPFS Molecular Imaging |
| Description | Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | company formed |
| URL | https://clinicaltrials.gov/show/NCT01532024 |
| Title | EDBT word building task |
| Description | We have also designed a new test implemented on the EDTB2 platform called the 'Word Building Task'. This is a new test of sustained attention which is essentially a verbal version of the EDTB2 counting tasks. It was the subject of an MSc project by Gemma Brown and the results of this study show that this new task is highly promising as a means of testing attention in patients with delirium. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2012 |
| Development Status | Under active development/distribution |
| Impact | The work is being presented at the European Delirium Association meeting in October 2012 and will shortly be submitted for publication. |
| Title | EDTB2 ICU product |
| Description | We have also designed a new protocol which allows the use of the EDTB2 in ICU settings, where most patients are unable to communicate verbally because they are intubated. This was another MSc project. The results of this project were highly encouraging. We believe this is a significant step forward; it is the first computerised test of attention in delirium to be used in ICU settings, and (to our knowledge) the second formal evaluation of cognitive testing in delirium in ICU. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2012 |
| Development Status | Under active development/distribution |
| Impact | The work is also being presented at the European Delirium Association meeting in October 2012 and will shortly be submitted for publication. |
| Title | EDTB2 software version |
| Description | In collaboration with NHS Greater Glasgow and Clyde we have produced the first software version of EDTB2. This is in the pilot phase of study at present. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2012 |
| Development Status | Under active development/distribution |
| Impact | Will lead to an app version |
| Title | Edinburgh Delirium Test Box |
| Description | The Edinburgh Delirium Test Box work has led to a new collaboration with the Medical Devices Unit of NHS Greater Glasgow and Clyde (Alexander Weir and Stuart Parks). We produced a new software version of the Edinburgh Delirium Test Box attentional test. This new test is called the DelApp and is implemented on the Android smartphone platform (though it is also readily implementable on other software platforms, eg. iOS). |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Actively seeking support |
| Impact | With the help of Edinburgh Bioquarter we have now set up a new partnership with Cambridge Cognition with a view to commercialising the DelApp for use by healthcare practitioners. As part of this process we are applying for a DPFS grant (outline submitted in July 2013; full application invited and will be submitted by 20 Nov 2013). The University of Glasgow is also a partner in this application (Geriatric Medicine - Prof David Stott, Clinical Neuropsychology - Prof Jonathan Evans, Anaesthesia and Critical Care - Dr Tara Quasim). A collaboration has been formed with Cambridge Cognition and a grant secured from Biomedical Catalyst for its further development. |
| Title | GMP material for Functional Optical Imaging in mice and man. |
| Description | The project focus is on the generation of optical molecular soultions for the preclinical acdemic, preclinical pharmaceutical and clinical communities. The main focus will be on generating a probe to detect human neutrophil elastase and perform in first in man study in acute lung injury. Most recent work supported by DPFS Portfolio Award The project has recieved £2M funding from HICF to increase the range of probes and indications. The leading compound NAP has been made to GMP completed preclinical testing and is approved by MHRA for administration to man. |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | A product has been made to GMP called NAP. This product has passed preclinical toxicology and is undergoing formulation. A company Edinburgh Molecular Imaging is a the late stage of becoming a spin out. |
| Title | KMO Inhibitors |
| Description | We have discovered that small molecule inhibitors of kynurenine-3-monoxygenase (KMO) reduce the severity of acute pancreatitis (AP) associated multiple organ failure (MOF) in rats, and have robust evidence that the pathway is upregulated in human patients with AP. This project builds on a patent GB0710781.6 (University of Edinburgh, June 2007, PCT: WO2008/149103) that covers the use of KMO inhibitors in organ failure and methods of monitoring therapy. We have established a strong team-based collaboration between Clinician Scientists, Drug Discovery Core facility, Chemistry and potential commercialisation partners. The project has two arms; 1) will evaluate lead stage KMO inhibitors identified by Roche, 2) in parallel to building a screening cascade and developing a discovery programme using in silico screening and HTP screening towards the identification of distinct and novel lead series, using AP-MOF as the primary indication. Most recent work supported by DPFS Portfolio Award |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | A significant collaboration with GSK uder the DPAc scheme has been agreed that will take the project through to launch is all stages are successful. From advanced hit to launched compound a significant translational pathway. |
| Title | New neuropsychological instrument for the diagnosis and monitoring of delirium |
| Description | Delirium is a common (at least 1 in 8 hospital inpatients) and severe acute neuropsychiatric syndrome mainly affecting older hospital inpatients, characterised by acute cognitive decline. Delirium is associated with multiple adverse outcomes, and is extremely expensive: the 1-year economic burden in the USA was recently estimated at between $38BN and $152BN. Despite its clear importance, delirium is grossly underdiagnosed: around 50% of cases go undetected. A fundamental cause of this is that diagnosis depends on subjective rating scales, which have inadequate sensitivity, specificity and inter-rater reliability. Therefore, better tests for delirium are urgently required. We have recently built and piloted a new neuropsychological instrument for the objective diagnosis of delirium. It shows excellent sensitivity for inattention and discriminates between delirium and dementia. Here we propose to develop this instrument by building a second prototype and validating this in larger clinical populations. A validated instrument would have wide potential clinical and research utility. Most recent work supported by DPFS Portfolio Award |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | We are currently actively evaluating the route to market for this device. It is likely that it will be combined with an Alzheimer's disease test also developed in Edinburgh into a to be formed spinout company NeuroDx. |
| Title | TRPM8 agonists as analgesics for chronic neuropathic pain |
| Description | " We have unique insights into the analgesic potential of TRPM8 ion channel-containing nerves in the skin, having discovered that they can over-ride pain inputs to the central nervous system, thus acting as a 'master-switch' in particular types of nerve injury.We have established a productive medicinal chemistry programme with SE Proof of Concept funding (ending December 2009) based on small molecule agonists of TRPM8 and synthesised a novel series of drug like compounds (ca. 100). Ca. 20 members have low µM potency in vitro and 6 show analgesic efficacy in vivo by topical and/or intrathecal administration in an established rodent model of neuropathic pain. IP space is excellent, and we have successfully reached the goal we set out to achieve at the start of SE funding. We have two main aims: Firstly to achieve rapid expansion of SAR space around our lead series, while establishing optimal potency, selectivity and in vivo analgesic efficacy. This will bring us to a position, well placed to submit a strong composition of matter patent on novel TRPM8 agonists for the treatment of neuropathic pain. Secondly, and key to our medicinal chemistry efforts, will be the development of at least one back-up series of compounds that will significantly strengthen our overall IP position and de-risk the project. This is central to the long term funding of the project either through WT Seeding Drug Discovery awards (applied for Nov 09), or partnership with various pharma companies. Future Outcome: Partnership with pharma through NeurocentRx and building of value in the company. It should be noted that this programme is anticipated to complement a broader PAIN PROGRAMME, encompassing a clinical study validating the target and approach, with this project forming a fast follower product as typically seen in pharma pipelines. Together they provide for an attractive licensable package. Most recent work supported by DPFS Portfolio Award" |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Actively seeking support |
| Impact | The programme has achieved lead compounds active in animal models, and specific for target with a structure confirming that a lead optimisation programme would be expected to deliver a clinical candidate. |
| Company Name | SESMOS Ltd |
| Description | A spin-out company of the School of Biological Sciences which started operations on Oct 14, 2011. Investors and co-Founders are (a) Siemens Technology Accelerator, Munich (Germany), and (b) Scottish Enterprises. Company mission: SESMOS Ltd links the acoustic resonator CMOS technology developed at Siemens with the single bead & single molecule screening technology developed at the Auer lab. SESMOS Ltd is a life sciences company that develops a novel integrated screening and validation process for drug discovery. The core of our technology is based on miniaturized small molecule libraries and fully quantitative and quality controlled biophysical screening technologies from the University of Edinburgh, linked with an innovative label free biosensor chip technology from Siemens AG. The company has secured funding and management support from Siemens and Scottish Enterprise and is currently located in the College of Science and Engineering at the University of Edinburgh, Scotland. The next twelve months will see the development of the proprietary SESMOS process, integration and subsequent first commercial screens being completed. If you would like to contact us, please email b.collier@sesmos.com or visit our Linkedin page The company was dissolved in 2014. |
| Year Established | 2011 |
| Impact | Delivering new chemical modulators for customer drug targets in a thoroughly quality controlled and quantitative process at lower costs compared to competition. |
| Website | http://www.sesmos.com/ |
| Company Name | Edinburgh Molecular Imaging (Functional Optical Imaging in mice and man) |
| Description | EMI has been formed from the team that received a DPFS award. The academic team continue to build indications with multiple awards. Raised £4M to build the company. Founded in February 2014 by leading academics from the University of Edinburgh who developed a versatile and disease focused approach to Optical Tracer Development. The company will build multiple probes and applications for testing in models and man |
| Year Established | 2014 |
| Impact | NA |
| Website | http://www.edinimage.com/ |
| Description | BIO2010(TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Biopartnering meeting with several Pharmaceutical and Biotechnology companies. Identified key questions for inclusion in future presentations |
| Year(s) Of Engagement Activity | 2010 |
| Description | BIO2011(TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | BioPartnering meeting with Pharmaceutical and Biotechnology companies Identifying increased interest as project has reached lead series and target is more accepted |
| Year(s) Of Engagement Activity | 2011 |
| Description | BioTrinity 2011 (TRPM8 agonists as analgesics for chronic neuropathic pain) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Individual meetings with Pharma companies and investors Awarenss of project and potential for company product. |
| Year(s) Of Engagement Activity | 2011 |
| Description | EDTB2 2011-2012 MRC Annual Review |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | Yes |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | MRC Annual review widely distributed to policy makers and the public none reported |
| Year(s) Of Engagement Activity | 2012 |
| Description | International users conference of Cellvizio (Functional Optical Imaging in mice and man) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | The International Conference of Cellvizio® Users (ICCU) is a unique event taking place annually during which Cellvizio users can share their knowledge and findings, develop guidelines for pCLE and discuss new indications Awareness of technology and project |
| Year(s) Of Engagement Activity | 2011 |